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Abstract
Background: Collagen Triple Helix Repeat Containing-1 (CTHRC1) and Nuclear factor (erythroid-derived 2)-like 3
(NFE2L3) may be useful biomarker candidates for the diagnosis of colorectal cancer (CRC) since they have shown
an increase messenger RNA transcripts (mRNA) expression level in adenomas and colorectal tumours when
compared to normal tissues.
Methods: To evaluate CTHRC1 and NFE2L3 as cancer biomarkers, it was generated and characterised several novel
specific polyclonal antibodies (PAb), monoclonal antibodies (MAbs) and soluble Fab fragments (sFabs) against
recombinant CTHRC1 and NFE2L3 proteins, which were obtained from different sources, including a human
antibody library and immunised animals. The antibodies and Fab fragments were tested for recognition of native
CTHRC1 and NFE2L3 proteins by immunoblotting analysis and enzyme-linked immunosorbent assay (ELISA) in
colorectal cell lines derived from tumour and cancer tissues.
Results: Both, antibodies and a Fab fragment showed high specificity since they recognised only their
corresponding recombinant antigens, but not a panel of different unrelated- and related proteins.
In Western blot analysis of CTHRC1, a monoclonal antibody designated CH21D7 was able to detect a band of the
apparent molecular weight of a full-length CTHRC1 in the human colon adenocarcinoma cell line HT29. This result
was confirmed by a double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) with the
monoclonal antibodies CH21D7 and CH24G2, detecting CTHRC1 in HT29 and in the colon adenocarcinoma cell
line SW620.
Similar experiments were performed with PAb, MAbs, and sFab against NFE2L3. The immunoblot analysis showed
that the monoclonal antibody 41HF8 recognised NFE2L3 in HT29, and leukocytes. These results were verified by
DAS-ELISA assay using the pairs PAb/sFab E5 and MAb 41HF8/sFab E5.
Furthermore, an immunoassay for simultaneous detection of the two cancer biomarkers was developed using a
Dissociation-Enhanced Lanthanide Fluorescent Immunoassay technology (DELFIA).
Conclusions: In conclusion, the antibodies obtained in this study are specific for CTHRC1 and NFE2L3 since they
do not cross-react with unrelated- and related proteins and are useful for specific measurement of native CTHRC1
and NFE2L3 proteins. The antibodies and immunoassays may be useful for the analysis of CTHRC1 and NFE2L3 in
clinical samples and for screening of therapeutic compounds in CRC.
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Colorectal cancer (CRC) is one of the most common
causes of cancer-related death in United States and
Western World [1]. During 2008, it was reported more
than 140000 new cases of CRC with more than 49000
deaths related to it [2]. Many patients with CRC may
develop liver metastases at some point during the course
of their disease [3]. Generally, colorectal cancer does not
show any symptoms until advanced stages of the dis-
ease. Therefore, early diagnosis is very important to
identify adenomatous tissue in pretumoral lesions to
remove it before it becomes neoplastic tissue.
Many molecular markers, including the carcinoem-
bryonic antigen (CEA), have been exploited for detecting
CRC. However, these biomarkers are not providing suf-
ficient sensitivity and reliability for the early detection of
CRC [4-8]. Thus, there is an urgent demand for
research into novel molecular markers that can serve as
diagnostic and prognostic markers for CRC. Collagen
Triple Helix Repeat Containing-1 (CTHRC1) and
Nuclear factor (erythroid-derived 2)-like 3 (NFE2L3)
may be useful biomarker candidates for the diagnosis of
CRC since they have shown an increase messenger RNA
transcripts (mRNA) expression level in colorectal
tumours when compared with normal tissues [9-12].
CTHRC1 is a 30 kDa secreted protein that has the
ability to inhibit collagen matrix synthesis. It is highly
expressed in cartilage, developing bones, and myofibro-
blasts during skin wound healing and its expression is
increased in fibroblasts and chondrocytic cells in
response to TGF-beta family members [13]. CTHRC1
inhibit TGF-beta signalling which can lead to a reduc-
tion in collagen type I deposition during vascular remo-
delling. In addition, it has been shown that CTHRC1 is
over-expressed in colorectal cancer [9-11]. In addition,
CTHRC1 is implicated in breast cancer, suggesting that
CTHRC1 expression in this type of tumour is associated
with cancer tissue invasion and metastasis [14]. In
recent studies it was suggested that CTHRC1 inhibition
may represent a potential method for decreasing mela-
noma resistance to conventional chemotherapy [15].
NFE2L3 is the third member of the family of NF-E2-
related- factors which are well-known for their partici-
pation in the basal expression and induction of defen-
sive genes in response to antioxidants [16]. NFE2L3 has
been described as a regulator of the antioxidant-
response element (ARE) [17]. Also, recently, a high
mRNA NFE2L3 expression has been detected in human
placenta and it has been related to placental and devel-
opmental expression [18]. NFE2L3 was also expressed in
relation to ovarian serous papillary carcinoma [19], solid
tumour formation in stem cells [20], and testicular semi-
noma diagnosis [21]. NFE2L3 is up-regulated in colorec-
tal cancer [12]. Recent studies showed the first in vivo
function of NFE2L3 and its link to tumour development
using a NFE2L3 - deficient mice. This study showed
that the absence of NFE2L3 predisposes mice to lym-
phoma development, suggesting a protective role of this
transcription factor in hematopoietic malignancies [22].
In this study, it had been obtained specific polyclonal
antibodies (PAbs), monoclonal antibodies (MAbs), and
soluble Fab fragments (sFAbs) against CTHRC1 and
NFE2L3 and some immunological assays for their detec-
tion in biological samples were established.
Methods
Cell culture and total cell extract preparation
The human colon adenocarcinoma cell lines HT29 and
SW620 were kindly supplied by Oryzon Genomics (Bar-
celona, Spain), originally acquired from the American
Tissue Culture Collection (ATCC)(Manassas, VA, USA).
The HT29 and SW620 cell lines were cultured with
F12 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Gibco, Grand Island, NY).
The cells were grown to confluency at 37°C and 5%
CO2. To obtain total cell extracts, cell monolayers were
washed twice with cold phosphate buffered saline (PBS),
and then were scraped and centrifuged at 1500 × rpm
for 5 min at 4°C. The cellular pellets were resuspended
in lysis buffer (10 mM Tris-HCl, pH 7.5, 140 mM NaCl,
5 mM EDTA, and 1.5% v/v Triton X-100) supplemented
with protease inhibitor cocktail complete EDTA free
(Roche, Basilea) and sonicated.
Preparation of bovine leukocytes suspensions
A blood sample from cow was collected for leukocytes
isolation. The cow received humane care in accordance
with the Guidelines for the accommodation and care of
animals used for experimental and other scientific pur-
pose according Animal Wellfare Laws (National Laws
RD 1201/2005). The animal experiment was approved
by Ethical Committee “Nucleo Zoosanitario” (No ES-
80790000095). The sample was collected into heparin
(Sigma, Inc., St.Louis, MO) and centrifuged at 1000 × g
for 15 min at room temperatu r e( R T ) .T h es u p e r n a t a n t
was removed and the pellet was treated with lysis buffer
(310 mM NH4Cl, 24 mM NaHCO3, 0.5 mM Na2 EDTA,
pH 7.4) for 15 min at room temperature. The sample
was centrifuged again at 1000 × g during 15 min and
the supernatant was removed. The pellet was resus-
pended in 400 μl 25 mM bicarbonate buffer.
Human lymphocytes purification
Fresh human lymphocytes were isolated from 50 ml
blood from a healthy volunteer blood donor by using
Histoplaque density gradients purchased from Sigma (St.
Louis, MO), following the protocol of the manufacturer.
The human blood sample was obtained in accordance
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sion from 2004 and Spanish Biomedical Law 121/
000104. Written informed consent was obtained from
the participants after oral and written information was
provided. The local ethics committee and the ethic com-
mittee of the consortium Oncnosis Pharma AIE
approved all procedures. The lymphocytes were lysed by
l y s i sb u f f e r( 1 0m MT r i s - H C l ,p H7 . 5 ,1 4 0m MN a C l ,5
mM EDTA, and 1.5% v/v Triton X-100) supplemented
with protease inhibitor cocktail complete EDTA free
(Roche, Basilea) and sonicated.
Cloning, expression and purification of recombinant
CTHRC1 and NFE2L3
A full-length of the human CTHRC1 gene was cloned
into the Gateway System expression vector pDEST17
(Invitrogen, Carlsbad, CA) from pDONR233 (Open Bio-
system BC014245), by recombination based on the
lambda recombination system. The sequence was con-
firmed with an automatic DNA sequencer. The new
vector was called pDEST17-CTHRC1.
A truncated form of NFE2L3 gene (844nt-2345nt)(cor-
responding to residues 30-694) was amplified by PCR
using cDNA obtained by reverse transcription of total
RNA from tumour cell line SW620 as described pre-
viously [23]. Two oligonucleotides NFE2L3 REVERSE
(5’-CTCACTTTCTCTTTCCCTTTTGGG-3’)a n d
NFE2L3 FORWARD (5’-AGAGAAAAGCAC-
GAAGCTGTG-3’) were designed and the amplification
reaction was carried out in a total volume of 50 μlw i t h
1 μl cDNA, 1 U DNA Taq polymerase (Roche), 200
μmol of each deoxyribonucleotide triphosphate, and 100
ng of each primer. Amplification involved 35 cycles at
94°C during 30 seconds, 55°C 30 seconds, 72°C 2 min-
utes 35 cycles, and a final extension step at 72°C during
10 minutes. The PCR product was purified and cloned
into the TOPO Gateway vector (Invitrogen, San Diego,
CA). The cloned fragment was subsequently transferred
to the expression vector pDEST17 by using the Gateway
system (Invitrogen). The new vector was called
pDEST17-NFE2L3. All sequences were confirmed by
sequencing.
In both cases the genes concerned were expressed as a
fusion protein that included His-Tag. The recombinant
CTHRC1 and NFE2L3 proteins were expressed by trans-
formation of E.coli BL21 strain (Invitrogen) cells. Over-
night cultures of transformed bacteria in LB
supplemented with 100 μg/ml of ampicillin and 50 μg/
ml carbenicillin were inoculated in fresh medium. Cul-
tures were grown at 37°C until they reached mid-log
phase (OD600 = 0.5). At that moment, expression of the
CTHRC1 and NFE2L3 recombinant proteins were
induced with the addition of L-arabinose to a final con-
centration of 0.2% w/v and incubated during three
hours at 37°C. Then, cultures were centrifuged, resus-
pended in lysis buffer containing 400 mM NaCl, 100
mM KCl, 10% glycerol, 0.5% Triton X-100, and 10 mM
Imidazol. Due to the insolubility of the proteins, an
additional step was done consisting in a ClGn-6 M
extraction and finally an additional purification step in a
column prepacked with Ni Sepharose (His GraviTrap™
from GE Healthcare, Buckinghamshire, UK) was carried
out.
Production of anti-NFE2L3 polyclonal antibodies
Purified recombinant NFE2L3 protein was used to
immunize rabbits. All rabbits received humane care in
accordance with the Guidelines for the accommodation
and care of animals used for experimental and other
scientific purpose according Animal Wellfare Laws
(National Laws RD 1201/2005). The animal experiment
was approved by Ethical Committee “Nucleo Zoosani-
tario” (No ES-80790000095). Aliquots containing 200 μg
of protein in 500 μlo fP B Sw e r em i x e dw i t ha ne q u a l
volume of Freund’s complete adjuvant for the first injec-
tion and Freund’s incomplete adjuvant for boosters. All
injections in rabbits were administered subcutaneously
in the leg of the rabbit. Injections were repeated 3 times
at 2-week intervals. Immunoglobulins presented in
serum were purified by a protein G column. The proto-
col suggested by the manufacturer was followed (GE
Healthcare Live Science, Uppsala, Sweden). The purified
immunoglobulins were dialysed against PBS, diluted
with glycerol (1:1) and stored at -20°C.
Production of anti-CTHRC1 and NFE2L3 monoclonal
antibodies
After immunization of mice with CTHRC1 or NFE2L3,
several MAbs specific for CTHRC1 or NFE2L3 were
obtained. Immunisation protocols, production and puri-
fication of MAbs were performed as previously
described [24,25]. All mice received humane care in
accordance with the Guidelines for the accommodation
and care of animals used for experimental and other
scientific purpose according Animal Wellfare Laws
(National Laws RD 1201/2005). The animal experiment
was approved by Ethical Committee “Nucleo Zoosani-
tario” (No ES-80790000095).
Production of anti-NFE2L3 Fab fragments
The antibody library FAB-310 (Dyax Corp, Cambridge,
MA) was used to select recombinant monoclonal anti-
bodies in the form of Fab fragments using the phage
display technology. FAB-310 is a human Fab library that
has an unique combination of immunoglobulin
sequences captured from human donors and synthetic
diversity in key antigen contact sites in heavy-chain
complementarity-determining regions 1 and 2 [26]. The
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the surfaces of M13 fused with pIII protein. Fab-310 has
ad i v e r s i t yo f3 . 5×1 0
10 (1.5 × 10
10 of kappa and 2 ×
10
10 of lambda). The selection procedure was done as it
was recommended by the manufacturer in the experi-
mental handbook of the product (Dyax Corp, Cam-
bridge, MA).
Positive Fab clones against recombinant CTHRC1 and
NFE2L3 were reformated to soluble Fab fragments
(sFab) by removing the pIII gene. The plasmids pMID21
carrying the Fab fragments were digested with MluI
enzyme, re-ligated and transformed into E. coli TG-1
starin. 94 randomly chosen individual colonies from
each selection round were analysed as recommended by
the manufacturer (Dyax Corp, Cambridge, MA). Super-
natant material was analysed in indirect ELISA using 0.1
μg CTHRC1, NFE2L3 or a non related biomarker as
negative control protein per well and detecting bonded
sFabs with anti C-myc HRP (Pierce, Waltham, MA) or
anti Fab peroxidase-conjugated antibodies (Sigma). Spe-
cific fragments were defined as sFabs clones that showed
a sign of ELISA at least 3 times higher in the plate cov-
ered with CTHRC1 or NFE2L3 than in the plate cov-
ered with negative control.
sFab producing clones were grown until they reached
a cellular density of 0.9 (OD600) on a stirrer at 37°C.
sFab production was induced with a final Isopropyl-
beta-d- thiogalactopyranoside (IPTG) concentration of 1
mM and the cultures were grown on a stirrer at 30°C
during the night. sFabs were separated from bacterial
sediment through centrifugation and purified by affinity
with protein A-Sepharose (GE Healthcare, Buckingham-
shire, UK).
Antibodies characterization
To determine the binding specificity of PAbs, MAbs,
and sFab, indirect ELISA trials were carried out using
non conjugated or biotin-conjugated antibodies.
CTHRC1 or NFE2L3 (30-694) were used to cover 96-
well Maxisorp plates (Nunc) in a 1-5 μg/ml concentra-
tion. The bindings with increasing biotin-conjugated
antibodies concentrations were measured with streptavi-
din-peroxidase (Sigma, Inc., St.Louis, MO). PAb, MAbs,
or sFabs binding with other non-related proteins, such
as lysozyme, fibrinogen, albumin, ovalbumin, human
IgG purchased from Sigma (St. Louis, MO) or with
other non-related cancer biomarkers were also
determined.
Western blotting
Immunologic detection of proteins was performed by
Western blot. 50-100 μg cellular extract was loaded in a
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE)
and then transferred to a nitrocellulose membrane. The
MAb CH21D7 against CTHRC1 was used in a concen-
tration of 25 μg/ml. The peroxidase-conjugated PAb
against NFE2L3 was used in a dilution of 1:2500. The
monoclonal antibody 41HF8 and the sFab E5 against
NFE2L3 were used in a concentration of 10 μg/ml. All
secondary antibodies coupled to horseradish peroxidase
directed against mouse IgG (Amersham) and rabbit IgG
were diluted 1:5000 and anti human Fab fragment
1:2000 (Sigma, Inc., St.Louis, MO).
Peroxidase and biotin conjugation of antibodies
The PAb were conjugated with peroxidase using the
periodate coupling method described by Nakane and co-
workers [27]. The PAbs, MAbs and sFabs were biotiny-
lated using (+)-Biotin N-hydroxysuccinimide ester fol-
lowing the protocol developed by Bayer and Wilchek
[28].
Colorimetric DAS-ELISA
Three assay formats were developed: one format to
detect CTHRC1 and two formats to detect NFE2L3.
In the CTHRC1 DAS-ELISA, the MAb CH21D7 was
used as captured antibody with a concentration of 0.5
μg/ml and biotin-conjugated CH24G2 as detection anti-
body with a concentration 0.5 ng/ml.
In the NFE2L3 DAS-ELISA, the sFab E5 was used as
captured antibody with a concentration of 1.2 μg/ml
and the PAb or biotin-conjugated 41HF8 as detection
antibody with a concentration of 5 ng/ml. In an alterna-
tive DAS-ELISA was used PAb as captured antibody
with a concentration of 5 ug/ml and biotin-conjugated
41HF8 as detection antibody with a concentration of 5
ng/ml.
The plates were blocked with 3% BSA in PBS 0.1%
Tween. Cellular extracts, or control antigens were added
to the wells and incubated 1 h 24°C or overnight at 4°C.
The control antigens were recombinant proteins
(CTHRC1 or NFE2L3). The negative control was
NFE2L3 in the CTHRC1 DAS-ELISA and CTHRC1 in
the NFE2L3 DAS ELISA. All further incubations were
performed at room temperature. The biotin-conjugated
antibodies were detected with the streptavidin-peroxi-
dase (Sigma, Inc., St.Louis, MO).
Dissociation-enhanced lanthanide fluorescent
immunoassay
The colorimetric DAS-ELISAs against CTHRC1 and
NFE2L3 were converted to a single Dissociation-
Enhanced Lanthanide Fluorescent Immunoassay (DEL-
FIA). Chessboard reagent titration experiments were
carried out to define optimal assay parameters. In the
DELFIA assay, sFab E5 and MAb CH21D7 were used as
captured antibodies with a concentration of 0.5 and 0.06
μg/well respectively in yellow plates. The
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(Perkin Elmer, Turku, Finland). The plates were blocked
with blocking solution (50 mM NaH2PO4, 6% trehalose,
0.1% BSA-TSA, 0.1% Germal II)(Sigma, Inc., St.Louis,
MO). Recombinant CTHRC1, NFE2L3 or a non-related
cancer biomarker as negative control protein were
added to the wells and incubated at room temperature
during 1 hour. The captured antigens were detected
with a mixture of PAb against NFE2L3 and biotin-con-
jugated CH24D7, followed by a mixture of Europium-
labelled anti rabbit antibody and Samarium-labelled
streptavidin. The signal was enhanced adding enhance-
ment solution (Perkin Elmer, Turku, Finland). The
fluorescence was measured with Envision Multilabel
Plate reader (Perkin Elmer, Turku, Finland). Antibody
levels were shown as fluorescence units.
Results
Characterization of the recombinant proteins and
antibodies
Several antibodies including PAb, MAbs and Fab frag-
ments were purified and characterized. They were origin-
ally identified by their recognition of CTHRC1 or NFE2L3
by indirect ELISA. The specificity of CH21D7 and
NFE2L3 was validated by Western blots and DAS-ELISA.
During the course of the screening those antibodies that
did not present cross-reactivity with not related proteins
as human fibrinogen, lysozyme, ovalbumin, bovine serum
albumin (BSA) and human IgGs, not either with other
cancer biomarkers (data not shown) or total E. coli cell
extract were considered specific. Also, those antibodies
that presented cross reactivity against the mentioned pro-
teins were discarded. The sFabs against CTHRC1 were
discarded since they did not recognize the recombinant
protein in Western blot, as well some MAbs against
NFE2L3. The MAbs CH21D7 and CH24G2 against
CTHRC1, and the PAb, the MAb 41HF8, and the sFab E5
against NFE2L3 were considered specific for their antigens
and were used in further analysis.
Immunoblot analysis of cellular extracts
The obtained PAb, MAbs and sFab were tested for spe-
cificity on Western blots. The SDS-PAGE was loaded
with cell extracts from two colon cancer cell lines
(HT29 and SW620), leukocytes and lymphocytes and
analyzed for NFE2L3 detection.
The results indicated that the MAb CH21D7 displayed
high specificity toward the native protein expressed in
t h ec e l ll i n eH T 2 9 ,d e t e c t ing a band of the apparent
molecular weight of a full-length CTHRC1 (~28 kDa)
(Figure 1A), however, non protein was detected in
SW620 or in the negative control (E.coli protein
extract). The MAb CH24G2 against CTHRC1
recognized only the recombinant and not the native
CTHRC1 (data not shown).
The PAb anti NFE2L3 recognized the recombinant
protein and several bands which had the molecular
weight of 77-, 65-, 30- and 28 kDa (Figure 1B) only in
leukocytes but not the cancer cell lines HT29 and
SW620. The MAb 41HF8 detected two bands of 77-and
65 kDa (Figure 1C) in leukocytes and a 77 kDa band in
lymphocytes (Figure 1D). This antibody detected two
bands of the molecular size of 77- and 44 kDa in HT29
and SW620. The sFab E5 against NFE2L3 recognized
only the recombinant and not the native NFE2L3 (data
not shown). A summary of Western blot results is
shown in Table 1.
Development of DAS- ELISA
The MAbs CH21D7 and CH24G7 were evaluated as
antibody pair in a sandwich ELISA for CTHRC1 detec-
tion, resulting in CH21D7 as capture antibody, and bio-
tin-conjugated CH24G7 as the detection antibody
(Figure 2A). The chessboard reagent titration showed
that optimal concentration for the assay was 0.5 μg/well
of CH21D7 as capture antibody and dilution 1:16000 of
biotin-conjugated CH24G7 as detection antibody. The
assay sensitivity, which was calculated by comparing the
signal of the CTHRC1 detection with the signal giving
by the negative control protein, was 2.0 ng/ml.
The PAb, MAb 41HF8 and sFab E5 specific for
NFE2L3 were combined to find the best antibody pairs
in sandwich ELISA for NFE2L3 detection.
The PAb (Figure 3A and 3B) or sFab E5 (Figure 3C
and 3D) were used as capture antibody, and biotin-con-
jugated PAb or biotin-conjugated 41HF8 or biotin-con-
jugated sFab E5 as detection antibodies.
The assay sensitivity of the NFE2L3 DAS-ELISA was
calculated by comparing the signal of the NFE2L3 detec-
tion with the signal giving by the negative control pro-
teins. The assays sensitivities were 0.5-2.0 ng/ml.
DAS-ELISA analysis of cellular extracts
In an initial attempt to evaluate CTHRC1 and NFE2L3
as biomarkers for cancer and the obtained antibodies
for their identification, the DAS- ELISA was used to
measure CTHRC1 and NFE2L3 in colon cancer cells
using known colon cancer cell lines as a model. The
CTHRC1 DAS-ELISA clearly detected the antigen in the
cell line HT29 and SW620, however, not signal was
obtained in the E.coli protein extract used as negative
control (Figure 2B). The NFE2L3 DAS-ELISA clearly
detected the antigen in the cell line HT29 and with a
lightly signal in the cell line SW620 and in leukocytes
(Figure 3B and 3D). Non signal was detected in the E.
coli protein extract which was used as negative control.
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The two colorimetric DAS-ELISAs developed were con-
verted to one DELFIA assay to multiplex the CTHRC1
and NFE2L3 detection (Figure 4). DELFIA technology
can be useful for the CTHRC1 and NFE2L3 detection
because it offers high sensitivity, wide dynamic range,
stability, possibility of multiplexing, and reducing the
amount of samples. The antibodies pairs selected for the
assay were chosen to avoid as much background as pos-
sible. Chessboard reagent titration experiments were
carried out to define optimal assay parameters. The
assay was optimised as it was recommended by the Per-
kin Elmer DELFIA guide. The combination of antibodies
pair chosen for the assay were MAbs CH21D7/CH24D7
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Figure 1 Detection of CTHRC1 and NFE2L3 in Western Blot. A: Recombinant- and native CTHRC1 analysed in total protein extracted from
HT29, and SW620 with MAb CH21D7. B, C & D: Recombinant- and native NFE2L3 analysed with PAb anti-NFE2L3 (B) or MAb 41HF8 (C) in total
protein extracted from HT29, SW620, leukocytes and lymphocytes (D)
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detection. The chessboard reagent titrations showed that
the optimal concentrations of antibodies were 0.06 μg/
w e l lM A bo fC H 2 1 D 7a n d0 . 5μg/well of E5 as capture
antibodies and a dilution 1:40000 of PAb and 1:500 of
CH24D7 as detection antibodies. Washing condition
was optimized to 6 washes after incubation with samples
and detection antibodies to reduce background. The
shaking speed was optimised to 125 rpm and the incu-
bation time with enhancement solution to 15 min to
increase the signal. The CTHRC1 readings were not
affected by the presence of the anti-NFE2L3 reagents or
NFE2L3 reading by the presence of anti-CTHRC1
reagents. The sensitivities of the assays for CH21D7 and
NFE2L3 detection were 0.5 - 2.0 ng/ml.
Discussion
The effort of this study was focus on CTHRC1 and
NFE2L3 as biomarkers stimulated by the strong evi-
dences of the differential expression of CTHRC1 and
NFE2L3 in CRC. Already in 2006 [29], it was demon-
strated with the patent EP2177628A2 that the CTHRC1
was related to CRC and could be used as marker for its
diagnosis since CTHRC1 was over-expressed in CRC
reaching mRNA level of 22-fold compared to normal
cells. In another study, it was shown that the CTHRC1
expression was dramatically up-regulated in several can-
cer types including CRC [30]. In the same way, the rela-
tion of NFE2L3 to cancer was studied by other
investigators, showing that 20 genes, including the gene
encoding NFE2L3, were up-regulated in colorectal can-
cer cells [12] and in adenomas when compared with
normal tissues [9-12]. Based on these investigations, it is
clear that the information available indicates that
CTHRC1 and NFE2L3 proteins are useful candidates to
determine the progress of CRC. For example, in our
patent EP2008/010665, we described a method for the
diagnosis and/or prognosis of colorectal tumour by
NFE2L3 detection [31].
Most of the studies of the CTHRC1 and NFE2L3
expression have been focused mainly on the analysis of
the mRNA levels, existing almost not results about their
protein levels. Therefore, it is really important to have
specific antibodies against these two biomarkers to facil-
itate further studies and make possible to set up immu-
nological assays for CRC diagnosis. Therefore, the
purpose of the present study was to select PAb, MAbs,
and sFab fragments against CTHRC1 and NFE2L3 pro-
teins and to develop immunoassays for CRC diagnosis.
We obtained several specific antibodies against the two
biomarkers which were analyzed carefully. However, we
concentrated our efforts on analysing CTHRC1 and
NFE2L3 in cell lines since they are the most frequently
used living systems in research and they can be used as
model for biomarker detection [32-34]. In addition, leu-
kocytes and lymphocytes were used for NFE2L3 detec-
tion since there is some information showing that
NFE2L3 mRNA is highly expressed in B cell and mono-
cyte lineage [16].
Our results indicated that the obtained antibodies
recognized their corresponding native proteins produced
in cell lines derived from cancer cells. Western blot
showed a band of the apparent molecular weight of a
full-length CTHRC1 in HT29 cells which corresponds
to the theoretical size of 26.2 kDa according to Collagen
triple helix repeat-containing protein 1 precursor from
UniProtKB at http://www.uniprot.org/uniprot/Q96CG8
[35]. The CTHRC1 detection in CRC cells was proved
by a DAS-ELISA DAS with the MAbs CH21D7 and
C H 2 4 G 2 .A l s o ,w ew e r ea b l et od e t e c tw i t ht h ea s s a y
the CTHRC1 protein in HT29 and SW620 cell lines,
but not in the negative control protein extract. This
DAS-ELISA had a sensitivity of 2.0 ng/ml. In the same
way, we showed the NFE2L3 protein expression in CRC
cells. Several protein bands were detected by Western
blot in CRC cell lines, leukocytes and lymphocytes cor-
responding to the molecular weight of 44-, 65-, and 77
kDa. The protein band pattern obtained in our result
was formed probably due the processing of the native
protein. In theory, the expected molecular weight of
NFE2L3 should be 76.1 kDa according to Nuclear factor
erythroid 2-related factor 3 from UniProtKB at http://
Table 1 Summary of the analysis of CTHRC1 and NFE2L3 by Western blot
Biomarkers and antibodies Cell extracts analyzed
HT29 SW620 E.coli cell extract Lymphocytes Leukocytes Other
CTHRC1 detection by
MAb CH21D7 Yes No No ND ND ND
MAb CH24G2 No No No ND ND ND
NFE2L3 detection by
PAb a-NFE2L3 No No No ND Yes ND
MAb 41HF8 Yes Yes No Yes Yes ND
sFab E5 No No No ND ND ND
ND: not determined
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Page 7 of 12www.uniprot.org/uniprot/Q9Y4A8[36], however, in the
practice the size of NFE2L3 can vary according to pro-
teins glycosylation or proteolysis. There are some indi-
cations of multiple NFE2L3 formation shown mainly in
the study of Zhang et al. Our results are partially in
concordance with the NFE2L3 size shown in this study
in which a synthesized protein of approximately 96-kDa
was subsequently converted into isoforms of approxi-
mately 90, 80, and 70 kDa [37]. In addition of the bands
mentioned above, their work showed two smaller bands,
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Figure 2 CTHRC1 detection by DAS-ELISA. A: Detection of the recombinant CTHRC1- and negative control protein (NFE2L3). B: Detection of
the native CTHRC1 protein in colon cell lines HT29 and SW620, and E. coli protein extract used as negative control. The MAb CH21D7 was used
as captured antibody and biotin-conjugated CH24G2 as detection antibody. The cellular extracts or control antigens were incubated in the wells
during 1 h at 24°C or overnight at 4°C.
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lation from two internal start codons at Met173 and
Met211 or from the proteolytic cleavage occurring
within a central region [37]. The native NFE2L3 detec-
tion was confirmed by DAS-ELISA with PAb, MAbs,
and sFabs against NFE2L3 in CRC cells and leukocytes.
A l s o ,w ew e r ea b l et od e t e c tw i t ht h i sD A S - E L I S At h e
NFE2L3 protein in HT29 and SW620 cell lines, but not
in the negative control protein extract. The assays sensi-
tivities were 0.5 - 5.0 ng/ml.
Multiplex detection of biomarkers can be useful in
diagnosis of CRC, therefore, we optimized an immu-
noassay for duplex detecti o no fC T H R C 1a n dN F E 2 L 3 .
We were able to combine the antibodies pairs of two
developed colorimetric DAS-ELISA to one DELFIA
assay without disturbing each other in the measurement.
When the two colorimetric DAS-ELISA were converted
to DELFIA assays for single measurement, the sensitivity
was increase to 3-fold. When two individual DELFIA
assays were combined, the sensitivity decreased to range
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Figure 3 NFE2L3 detection by DAS-ELISA. A&B :Detection of the recombinant NFE2L3- and negative control protein (CTHRC1) and analysis
of NFE2L3 in protein extracts from HT29, SW620, leukocytes, and E. coli protein extract with the antibodies pair PAb a-NFE2L3 and MAb 41HF8.
C&D :Detection of the recombinant NFE2L3- and negative control protein (CTHRC1) and analysis of NFE2L3 in protein extracts from HT29,
SW620, leukocytes, and E. coli protein extract with the pair sFab E5 and MAb 41HF8. The samples were incubated during 1 h at 24°C or
overnight at 4°C.
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Figure 4 Double detection of CTHRC1 and NFE2L3 by DELFIA. A: Detection of recombinant CTHRC1 and a non-related biomarker as
negative control protein. B: Detection of recombinant NFE2L3 and a non-related biomarker as negative control protein. The sFab E5 and MAb
CH21D7 were immobilised in DELFIA yellow plate. The plates were blocked with blocking solution. A mixture of recombinant CTHRC1 and
NFE2L3 was added to the wells. The captured antigens were detected with rabbit PAb a-NFE2L3 and biotin-conjugated CH24D7, followed by
Europium-labelled anti rabbit antibodies and Samarium-labelled streptavidin. The signal was amplified by enhancement solution. The amount of
antibodies was detected by dissociation-enhanced time-resolved fluoroimmunoassays research fluorometer.
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develop an assay to detect the two biomarkers simulta-
neously. The DELFIA assay was successfully developed.
Even, when the sensitivity was not improved in this case
with DELFIA several advantages have been incorporated
to the original DAS-ELISA with this technology. Some
of these advantages can be useful in medical diagnostic
including cost-, time-, and samples- reduction and sig-
nal stability. The sensitivity of our DELFIA assay is in
the process to be improved by replacing the pre-labelled
secondary antibodies with primary lanthanide-labelled
antibodies.
It will be interesting to test our antibodies and assays
with other biological samples than cell lines such as
serum or tissues from CRC patients. In a first effort to
optimize the assay conditions for serum analysis with
our assays, it was performed spike-in experiments with
negative serum to determine if serum component can
affect the detection level of CTHRC1 and NFE2L3. The
diagnostic/prognostic in the serum of patients can be
limited by the presence of highly abundant albumin and
immunoglobulins that constitute approximately 60-97%
of the total serum proteins [38] or by other components.
However, in our study we were not able to see any dif-
ferences between the detection with and without serum,
indicating that measurement of our biomarkers is unaf-
fected by highly abundant proteins in serum (data not
shown). We are in the process to improve the assay sen-
sitivity and performance by labelling the PAb, MAb
CH24D7 and MAb 41HF8 directly with Samarium and
Europium. An additional application of our DELFIA
CTHRC1 NFE2L3 assay may be mass screening of ther-
apeutic compounds relating to CRC.
Conclusions
In conclusion, the present study offers a simple and reli-
able method for the diagnosis of CRC based on
CTHRC1 and NFE2L3 detection by a double sandwich
antibody ELISA or DELFIA technology. The selected
antibodies can be useful for detection of the two bio-
markers in tissue samples or serum and in studies of
these two biomarkers.
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